- Conditions
- PFIC1, PFIC2
- Interventions
- A4250 (odevixibat), Placebo
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Alagille Syndrome
- Interventions
- Odevixibat, Placebo
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- Not listed
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 5 more
- Conditions
- Alagille Syndrome
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Kansas City, Missouri + 6 more
- Conditions
- Progressive Familial Intrahepatic Cholestasis
- Interventions
- Odevixibat
- Drug
- Lead sponsor
- Albireo
- Industry
- Eligibility
- Not listed
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alagille Syndrome
- Interventions
- Odevixibat
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 18
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 14 more
- Conditions
- Pregnancy Related
- Interventions
- Not listed
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- Female only
- Enrollment
- 20 participants
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Biliary Atresia
- Interventions
- Odevixibat, Placebo
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Up to 111 Days
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 25 more
- Conditions
- Progressive Familial Intrahepatic Cholestasis
- Interventions
- A4250 (odevixibat)
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- 0 Months to 100 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 7 more
- Conditions
- Biliary Atresia
- Interventions
- Odevixibat
- Drug
- Lead sponsor
- Albireo, an Ipsen Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 6 more